Replies to post #3251 on Pulmatrix Inc (PULM)

[riskon]

Not sure... could be as early as next week; with the 2/23/2021 webinar on alternative delivery mechanisms for therapeutics & vaccines scheduled....

Are we about to see an announcement of PUR1800 (or even the resurfacing of PUR5700) being studied/used as therapeutic for COVID-19? A JnJ / Pulmatrix collaboration to be announced in addition to their target indication of COPD & Lung Cancer?

Lots of literature out there on P38 MAPK Kinase Inhibitors being repurposed for Covid-19 therapeutic treatment.

Example Article 1:
"The authors conclude that “safe and well tolerated p38 MAPK inhibitors that are already in clinical development could be readily repurposed in randomized, controlled trials enrolling patients at risk for serious COVID-19 complications.”

https://sparkmed.stanford.edu/dr-grimes-authors-paper-on-p38-mapk-pathway-in-covid-19/

Example Article 2:
"A number of p38 inhibitors are in the clinical stage and should be considered for clinical trials in serious COVID-19 infection."

https://pubmed.ncbi.nlm.nih.gov/32422320/

PUR1800 Fact Sheet: